Baudax Bio to Present at the NobleCon Pain Management Investor Forum

Rhea-AI Summary

MALVERN, Pa., Oct. 5, 2021 – Baudax Bio (NASDAQ:BXRX) announced a corporate presentation at the NobleCon Pain Management Investor Forum on October 7, 2021. The presentation will be available for registered attendees starting at 11:00 a.m. Eastern Time and can be accessed on Baudax's investor website. Baudax Bio focuses on innovative products for acute care settings, including ANJESO, a 24-hour intravenous NSAID for managing moderate to severe pain, along with a pipeline of neuromuscular blocking agents and a proprietary reversal agent.

News Market Reaction – BXRX

-1.82%

-1.82% Session move

In the trading session that priced this news, BXRX declined 1.82%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MALVERN, Pa., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, today announced that management will give a corporate presentation followed by a question and answer session at the NobleCon Pain Management Investor Forum being held virtually on Thursday, October 7, 2021.

The presentation will be made available to registered attendees (cost free) for on-demand listening beginning Thursday, October 7, 2021 at 11:00 a.m. Eastern Time and may be accessed on the “Events” page within the investors section of the Baudax Bio website at https://www.baudaxbio.com/news-and-investors. The recording will be archived as part of its C-Suite Series at https://www.channelchek.com/c-suite.

About Baudax Bio

Baudax Bio is a pharmaceutical company focused on commercializing and developing innovative products for acute care settings. ANJESO is the first and only 24-hour, intravenous (IV) COX-2 preferential non-steroidal anti-inflammatory (NSAID) for the management of moderate to severe pain. In addition to ANJESO, Baudax Bio has a pipeline of other innovative pharmaceutical assets including two novel neuromuscular blocking agents (NMBAs) and a proprietary chemical reversal agent specific to these NMBAs. For more information, please visit www.baudaxbio.com.

CONTACTS:

Investor Relations Contact:
Argot Partners
Sam Martin / Claudia Styslinger
(212) 600-1902
baudaxbio@argotpartners.com

Media Contact:
Argot Partners
David Rosen
(212) 600-1902
david.rosen@argotpartners.com

FAQ

When is Baudax Bio's presentation at the NobleCon Pain Management Investor Forum?

Baudax Bio's presentation is scheduled for October 7, 2021 at 11:00 a.m. Eastern Time.

How can I access Baudax Bio's presentation?

The presentation can be accessed for free by registered attendees on Baudax Bio's investor website.

What innovative products does Baudax Bio focus on?

Baudax Bio focuses on products for acute care, including ANJESO, a 24-hour intravenous NSAID, and two novel neuromuscular blocking agents.

What is ANJESO used for?

ANJESO is used for the management of moderate to severe pain as a 24-hour intravenous COX-2 preferential NSAID.

Where can I find more information about Baudax Bio?

More information about Baudax Bio can be found on their official website.